Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States.
The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung.
It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid.
Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 10, 23 | -0.15 Increased by +68.60% | -0.54 Increased by +72.09% |
| Mar 17, 23 | -0.21 Decreased by -136.21% | -0.21 |
| Nov 14, 22 | -0.30 Increased by +43.40% | -0.36 Increased by +16.67% |
| Aug 15, 22 | -0.30 Increased by +48.28% | -0.46 Increased by +34.78% |
| May 16, 22 | -0.48 Increased by +69.23% | -0.43 Decreased by -11.63% |
| Mar 30, 22 | 0.58 Increased by +130.53% | -0.62 Increased by +193.55% |
| Nov 12, 21 | -0.53 Increased by +99.03% | -0.72 Increased by +26.39% |
| Aug 12, 21 | -0.58 Increased by +47.79% | -0.69 Increased by +15.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 0.00 Decreased by -100.00% | -4.47 M Increased by +67.53% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 2.30 M Decreased by -91.13% | -11.51 M Decreased by -188.25% | Decreased by -500.22% Decreased by -1.09 K% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -14.47 M Increased by +7.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 653.00 K Increased by +20.93% | -9.48 M Increased by +44.47% | Decreased by -1.45 K% Increased by +54.08% |
| Mar 31, 22 | 1.65 M Increased by +344.20% | -13.76 M Increased by +62.50% | Decreased by -834.89% Increased by +91.56% |
| Dec 31, 21 | 25.94 M Increased by +5.55 K% | 13.04 M Increased by +145.17% | Increased by +50.28% Increased by +100.80% |
| Sep 30, 21 | 1.46 M Increased by +76.54% | -15.70 M Increased by +11.12% | Decreased by -1.08 K% Increased by +49.66% |
| Jun 30, 21 | 540.00 K Decreased by -25.93% | -17.07 M Increased by +16.07% | Decreased by -3.16 K% Decreased by -13.30% |